Quantum BioPharma Ltd. has concluded a global settlement agreement with former Executive Chairman and CEO Dr. Raza Bokhari, resolving all outstanding legal disputes stemming from a 2021 proxy contest. The settlement involves Bokhari paying the company $2.35 million, effectively closing legal actions in both the United States and Canada.
The agreement, signed by Co-Chairmen Zeeshan Saeed and Anthony Durkacz, includes provisions barring future litigation between the parties. Importantly, both Quantum BioPharma and Bokhari have emphasized that the settlement does not constitute an admission of wrongdoing, with both asserting their actions were in the company's best interests.
This resolution represents a significant milestone for Quantum BioPharma, as it provides non-dilutive capital and removes potential legal uncertainties that could have impacted the company's strategic operations. The settlement allows the biopharmaceutical company to maintain its focus on developing innovative treatments for neurodegenerative and metabolic disorders.
The financial injection comes at a time when the company continues to advance its research portfolio, including its lead compound Lucid-MS, which shows potential in preventing and reversing myelin degradation associated with multiple sclerosis. Additionally, the company maintains strategic investments and a partial ownership stake in Celly Nutrition Corp., further diversifying its business interests.
